STERIS plc

Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)

Xodus Medical, a private surgical-safety device maker near Pittsburgh, agreed to be acquired by STERIS (NYSE: STE). STERIS management framed the deal as a bolt-on that expands its operating-room consumables portfolio, noting Xodus has grown at double-digit rates with a steady new-product stream. No purchase price or terms were disclosed; deal impact for STE shareholders appears incremental rather than transformative. Goldman Sachs and Jones Day advised STERIS; J.P. Morgan and Morgan Lewis advised Xodus.

•13d ago

STERIS Expands Healthcare Consumables Offering with Definitive Agreement to Acquire Xodus Medical, a Specialty Surgical Products Business Focused on Patient and OR Staff Safety

STERIS signed a definitive agreement to acquire Xodus Medical, a specialty surgical products maker, for $2.1 billion at closing, expected to close by December 31, 2026. Cash tax benefits with an NPV of roughly $300 million reduce the net purchase price to about $1.8 billion, with up to $150 million in earnout tied to 2028 performance targets. Xodus is expected to deliver about $245 million of 2026 revenue and $135 million of adjusted EBIT, and the deal is anticipated to be accretive to top-line growth, margins, and adjusted earnings. Financing will be primarily debt-funded, and STERIS will provide a revised fiscal 2027 outlook including Xodus after closing.

•13d ago

STERIS Announces Financial Results for Fiscal 2027 First Quarter

STERIS reported fiscal Q1 revenue of $1.5 billion, up 7% year-over-year, with adjusted EPS rising to $2.59 from $2.34 in the prior year. The company reiterated its full-year fiscal 2027 guidance for revenue growth of 7-8% and adjusted EPS of $11.10 to $11.30, though it raised capital expenditure expectations to $450 million to support a new Center of Excellence. A restructuring plan to consolidate formulated chemistries manufacturing in North Carolina is expected to incur $55 million to $70 million in pre-tax charges, with completion anticipated in fiscal 2030.

•2mo ago

STERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina

STERIS announced a $600 million investment to build a formulated chemistries Center of Excellence in North Carolina, marking the largest single-site investment in company history. The new 600,000 square-foot campus near the Raleigh-Durham region is expected to create 335 jobs and become operational in 2-3 years, eventually consolidating manufacturing from St. Louis and Plymouth. CEO Dan Carestio highlighted that the move will optimize the U.S. manufacturing network and support long-term global growth in infection prevention and contamination control.

•2mo ago

STERIS Raises Dividend to $0.69 per share

STERIS plc increased its quarterly interim dividend by $0.06 to $0.69 per share, marking the company's 21st consecutive year of dividend growth. The dividend is payable on September 25, 2026, to shareholders of record at the close of business on September 4, 2026. The company is a global provider of infection prevention products and services supporting patient care.

•2mo ago

STE: DEF 14A · proxy statement

STERIS plc filed its 2026 Proxy Statement for the annual meeting scheduled for July 31, 2026, highlighting a record fiscal year with revenue growing 8.7% to $5.94 billion and net income rising to $782.3 million. The filing includes routine proposals for the election of directors, ratification of Ernst & Young as auditor, and a say-on-pay advisory vote, with the board unanimously recommending a vote for all proposals. CEO Daniel Carestio’s compensation is heavily variable, with 90.3% tied to performance metrics, resulting in a total realized value of approximately $8.7 million in equity awards and a $1.73 million cash bonus for fiscal 2026.

SEC DEF 14A•4mo ago

STE: 10-K · periodic report

STERIS plc reported fiscal 2026 revenues of $5.94 billion, an 8.7% increase year-over-year, driven by organic growth, pricing, and favorable currency movements. Operating income rose 27.1% to $1.1 billion, benefiting from lower restructuring costs and the absence of the $48.2 million Illinois EO litigation settlement recorded in the prior year. The company generated $982.9 million in free cash flow and maintained a debt-to-total capital ratio of 21.3%. On May 5, 2026, the Board authorized a new $1 billion share repurchase program, replacing the previous program which had $75 million remaining. The company also increased its quarterly dividend to $0.63 per share. STERIS operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. All segments showed double-digit revenue growth, with Healthcare contributing the largest share. The company highlighted ongoing risks related to geopolitical instability, tariffs, and regulatory compliance, particularly regarding ethylene oxide sterilization operations.

SEC 10-K•4mo ago

STERIS Announces Financial Results for Fiscal 2026 Fourth Quarter and Full Year

STERIS reported full year fiscal 2026 revenue of $5.9 billion, up 9% year-over-year, with constant currency organic revenue growth of 7%. As reported, diluted EPS from continuing operations increased to $7.93, and adjusted EPS per diluted share rose to $10.17, up from $9.22 in fiscal 2025. The company expects fiscal 2027 revenue to grow 7-8% YoY, with constant currency organic revenue growth of 6-7% and adjusted EPS in the range of $11.10 to $11.30. STERIS's Board of Directors has authorized a new $1 billion share repurchase program to replace the prior authorization.

•5mo ago

STERIS Appoints Pierre Boulud to Board of Directors

STERIS plc announced the appointment of Pierre Boulud to its Board of Directors, effective May 5, 2026. Boulud brings extensive leadership experience from his role as CEO of bioMérieux and prior positions at Ipsen and The Boston Consulting Group. STERIS expressed confidence in his ability to contribute to the company's strategic and operational goals.

•5mo ago